June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Evaluation of systemic safety by intravitreal injections of vascular endothelial growth factor inhibitors for diabetic macular edema: systematic review of literature and meta-analysis
Author Affiliations & Notes
  • Yasuko Yanagida
    University of Tokyo, Tokyo, Japan
  • Takuhiro Yamaguchi
    University of Tokyo, Tokyo, Japan
  • Takashi Ueta
    University of Tokyo, Tokyo, Japan
  • Footnotes
    Commercial Relationships Yasuko Yanagida, None; Takuhiro Yamaguchi, None; Takashi Ueta, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2440. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yasuko Yanagida, Takuhiro Yamaguchi, Takashi Ueta, ; Evaluation of systemic safety by intravitreal injections of vascular endothelial growth factor inhibitors for diabetic macular edema: systematic review of literature and meta-analysis. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2440.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate whether intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors for diabetic macular edema (DME) affect the systemic vascular and mortality risk.

Methods: According to a recent review conducted by American Academy of Ophthalmology (AAO), high quality randomized controlled trials (RCTs) on ranibizumab for DME were chosen based on the predefined criteria including enrolling a minimum of 100 participants, with follow-up for at least one year, and completion rate of at least 80%. The number of events in cerebrovascular accidents (CVAs), myocardial infarction (MI) and death were extracted from the reports of the RCTs. Meta-analysis by fixed effect model was conducted due to insignificant heterogeneity among the included studies.

Results: After screening of the corresponding abstracts and full text papers, four trials totalling 1786 patients with DME were included. In all the four RCTs, patients with recent systemic vascular events were not included. In two RCTs ranibizumab was administered monthly for two years, and in the other two RCTs as needed for one year. In patients treated with 0.3 mg/0.5 mg ranibizumab, the risk ratios (RR) and 95% confidence interval (CI) for CVA, MI and total death compared to the control groups were 0.640 (0.313-1.310, P=0.222), 0.785 (0.371-1.659, P=0.526), and 1.461(0.696-3.065, P=0.316).

Conclusions: Intravitreal injections of VEGF inhibitors for DME were not associated with the increased risk of CVA, MI or mortality, although data on systemic safety for high risk patients has been remained unknown.

Keywords: 499 diabetic retinopathy • 503 drug toxicity/drug effects  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×